Skip to content
Research/Immune Modulation/Delgocitinib

Delgocitinib

Delgocitinib is a Janus kinase (JAK) inhibitor primarily used for its immunomodulatory effects, particularly in treating inflammatory skin conditions like atopic dermatitis. By inhibiting JAK pathways, it reduces inflammation and immune response, which is crucial for managing chronic inflammatory conditions that can impact longevity and overall health.

Intelligence Profile

Science

Delgocitinib functions primarily as a Janus kinase (JAK) inhibitor. JAKs are enzymes that play a crucial role in the signaling pathways involved in inflammation and immune responses. By inhibiting the JAK pathways, delgocitinib disrupts the signaling cascade that leads to the production of inflammatory cytokines.

The inhibition of JAKs by delgocitinib reduces the inflammatory response that characterizes conditions such as atopic dermatitis, chronic hand eczema, and other inflammatory skin disorders. This mechanism helps in alleviating symptoms like itching, redness, and swelling. The efficacy of delgocitinib in these conditions has been demonstrated in clinical studies, such as the Phase IIb trial assessing its use in atopic dermatitis (PMID: 42483929) and trials on chronic hand eczema (NCT03683719).

It is important to note that while JAK inhibition addresses inflammation, its impact on the entire immune system requires careful monitoring for side effects, as JAK inhibitors can potentially affect normal immune function.

Disclaimer: This information is intended for educational and informational purposes only and should not be used as a substitute for professional medical advice.